Acute myeloid leukemia trials in Belgium

In Belgium 27 Also abroad 761

27 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Edegem, Gent, Leuven
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Where
Anderlecht, Antwerp, Brugge, Charleroi, Edegem, Geel, Gent, Hasselt, La Louvière, Leuven, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
875 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07223814 · EU 2025-522767-15-00
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Gent
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 3Taking people
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Where
Antwerp, Brugge, Brussel, Leuven, Roeselare, Yvoir
Age
18 years to 75 years
People
650 worldwide
Run by
University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00
Phase 3Taking people
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Where
Bruges, Edegem, Genk, Ghent, La Louvière, Leuven, Ottignies, Roeselare
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00
Phase 3Taking people
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
Where
Anderlecht, Antwerp, Gent, Jette, Leuven, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
180 worldwide
Run by
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
See details and how to join2024-512753-24-00 · EU 2024-512753-24-00
Phase 3Taking people
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Where
Gent
Age
12 years and over
People
468 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00
Phase 3Taking people
Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)
Where
Gent, Leuven
Age
Up to 64 years
People
128 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-506546-23-00 · EU 2023-506546-23-00
Phase 3Taking people
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Where
Brugge, Gent, Jette, Liège, Roeselare, Verviers
Age
18 years and over
People
1,300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Ghent
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 3Taking people
CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)
Where
Brussels, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
Up to 64 years
People
675 worldwide
Run by
Prinses Maxima Centrum voor Kinderoncologie B.V.
See details and how to join2023-504999-25-00 · EU 2023-504999-25-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Liège
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Where
Anderlecht, Antwerp, Brugge, Gent, Jette, Leuven, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
448 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT06652438 · EU 2024-512733-32-00
Phase 2/3Taking people
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Where
Anderlecht
Age
18 years to 80 years
People
312 worldwide
Run by
Moleculin Biotech, Inc.
See details and how to joinNCT06788756 · EU 2024-518359-47-00
Phase 1Taking people
A Study to Assess Adverse Events and How Pivekimab Sunirine Moves Through the Body of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Where
Gent
Age
Up to 17 years
People
18 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-520125-36-00 · EU 2024-520125-36-00
Phase 3Taking people
Study comparing thymoglobulin to grafalon, two treatments used to prevent graft versus host disease in elderly patients with acute myeloid leukemia or myelodysplastic syndrome and receiving an allogeneic stem cell transplantation with an unrelated matched donor after a reduced intensity conditioning regimen
Where
Sint-Lambrechts-Woluwe
Age
18 years and over
People
334 worldwide
Run by
Assistance Publique Hopitaux De Paris
See details and how to join2023-504555-27-00 · EU 2023-504555-27-00
Phase 3Taking people
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Where
Antwerp, Brugge, Hasselt, Liège, Roeselare, Yvoir
Age
18 years and over
People
245 worldwide
Run by
Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00
Phase 1/2Taking people
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Where
Antwerp, Ghent, Leuven, Roeselare
Age
12 years and over
People
606 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04988555
Phase 4Taking people
PTX3-targeted Antifungal Prophylaxis
Where
Gent, Leuven, AZ Sint-Jan Brugge-Oostende AV
Age
18 years and over
People
410 worldwide
Run by
Bochud Pierre-Yves
See details and how to joinNCT03828773 · EU 2024-517211-79-00
Phase 3Taking people
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Where
Antwerp, Brussels, Ghent, Leuven, Liège, Yvoir
Age
18 years and over
People
227 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT07075016
Phase 2Taking people
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients
Where
Brussels, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
1 month to 18 years
People
60 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT06262438 · EU 2023-505000-27-01
Phase 3Taking people
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Where
Brussels, Ghent, Leuven, Liège
Age
Up to 18 years
People
170 worldwide
Run by
Vastra Gotaland Region
See details and how to joinNCT05477589
Phase 3Taking people
NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years
Where
Brussels, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
Up to 64 years
People
730 worldwide
Run by
Vaestra Goetalandsregionen
See details and how to joinNCT01828489 · EU 2024-518254-16-00
Phase 2Taking people
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
Where
Brussels
Age
Up to 18 years
People
89 worldwide
Run by
Associazione Italiana Ematologia Oncologia Pediatrica
See details and how to joinNCT04793919 · EU 2024-518669-83-00
Phase 2Taking people
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Where
Anderlecht, Antwerp, Brugge, Gent, Jette, Leuven, Roeselare, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years to 75 years
People
114
Run by
University of Liege
See details and how to joinNCT03852407 · EU 2024-518568-11-00